Pfizer hails the Quebec government for its new policy on rare diseases and calls on the federal government to adopt policies similar to those of Quebec

KIRKLAND, QC, June 7, 2022 /CNW/ – Pfizer Canada welcomes the Government of of Quebec announcement of the creation of the first Quebec rare disease policy. This policy, which was the subject of a consultation process mobilizing several organizations involved in rare diseases, aims to improve the training of doctors and health professionals, to optimize the accessibility of health care and services and to prioritize the promotion and support of research. Pfizer Canada also applauds the Quebec the government’s commitment to innovation in the development and access to innovative treatments.

According to the Regroupement québécois des Maladies Orphanes (RQMO), approximately one person in 20 is affected by a rare disease, totaling approximately 500,000 Quebecers.1

“People living with a rare disease, as well as their families and loved ones, deserve more healthcare solutions and Pfizer Canada is committed to working with all levels of government, provincial and federal, as well as the rare disease community to develop a Disease Control Strategy,” said Fred Small, Country Lead, Rare Diseases Business Unit, Pfizer Canada. “We would like to thank the government for Quebec for their commitment to bringing together a diverse group of individuals with a common goal of improving the current system that will better support patients with rare diseases. This initiative has been a great opportunity for all players in the healthcare ecosystem to come together and co-create a world-class and sustainable rare disease framework that supports those living with someone living with a rare disease. a rare disease or those who care for it, along the continuum – from detection and screening to diagnosis and access to treatment.”

In order to continue to build on the optimism generated by the Quebec the government’s announcement for the implementation of an effective and sustainable strategy for rare diseases through QuebecPfizer Canada invites the federal government to follow of Quebec example and will unveil its plans for the development of a comprehensive pan-Canadian policy framework, which is long awaited by the entire rare disease community in Canada.

For more than two decades, Pfizer has provided essential treatment options for patients with rare diseases. The light at of Quebec announcement, we take this opportunity to share our recommendations regarding the development of a national drug strategy for rare diseases.

Our recommendations are based on five principles: patient focus, integration of patient/clinician expertise, adoption of a differentiated and tailored approach to rare diseases, sustainability through new reimbursement models and commitment to the best evidence.

Pfizer remains committed to supporting Quebecers and Canadians living with rare diseases, as well as those around the world by working collaboratively with multiple stakeholders, while playing a leadership role in the development and commercialization of new treatment options. rare diseases.

Rare Pfizer Disease

Rare diseases include some of the most serious diseases and affect millions of patients worldwide, presenting an opportunity to apply our knowledge and expertise to help make a significant impact in addressing unmet medical needs. Pfizer’s focus on rare diseases is underpinned by more than two decades of experience, a dedicated research unit focused on rare diseases, and a global portfolio of multiple drugs in a number of therapeutic areas, including hematology, neuroscience and inherited metabolic disorders.

Pfizer Rare Disease combines pioneering science and a deep understanding of how diseases work with insights from innovative strategic collaborations with academic researchers, patients and other companies to bring treatment options to underserved patients.

About Pfizer Canada

Pfizer Canada ULC is the Canadian subsidiary of Pfizer Inc., one of the world’s leading biopharmaceutical companies. Our diverse healthcare portfolio includes some of the world’s best known and most prescribed medicines and vaccines. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything we do, from our disease awareness initiatives to our community partnerships. To learn more about Pfizer Canada, visit or you can follow us on LinkedIn, Facebook, Twitter Where Youtube.

SOURCE Pfizer Canada ULC

For further information: Pfizer Canada Corporate Affairs, 1-866-9-PFIZER (1 866 973-4937), [email protected]

Comments are closed.